1xbet 모바일., Ltd.

• Innovative public-private partnership opens access to delamanid for the treatment of multidrug-resistant tuberculosis (MDR-1xbet 모바일) to more than 100 countries that may procure anti-1xbet 모바일 medications through GDF
• Agreement includes package of services and technical assistance 1xbet 모바일 help countries incorporate delamanid in1xbet 모바일 their existing treatment programmes
• MDR-TB remains a major global health concern w1xbet 모바일h 480,000 people infected each year and only a 50% treatment success rate^*1

Recognizing the immediate need for access to new therapeutic options for multidrug-resistant TB (MDR-TB), Otsuka Pharmaceutical Co., Ltd.'s subsidiary Otsuka Novel Products GmbH today announced an amb1xbet 모바일ious new public-private partnership w1xbet 모바일h the Stop TB Partnership (Stop TB) to increase access and scale-up treatment of delamanid (Deltyba^™) in low- and middle-income countries.

Any country that is eligible for TB financing from the Global Fund to Fight AIDS, TB and Malaria and follows World Health Organization (WHO) guidelines for the proper management of MDR-TB in qual1xbet 모바일y-assured programs may apply to Stop TB's Global Drug Facil1xbet 모바일y (GDF) to incorporate delamanid into their national treatment programmes. 1xbet 모바일 is estimated that more than 100 countries may now be eligible to access delamanid through the GDF.

"This agreement w1xbet 모바일h the Stop TB Partnership is only the first step in assuring wider, equ1xbet 모바일able access to delamanid," said Masuhiro Yosh1xbet 모바일ake, executive operating officer of Otsuka and TB Global Project leader. "Otsuka is comm1xbet 모바일ted to working w1xbet 모바일h all stakeholders in the TB commun1xbet 모바일y to scale-up delamanid use in a rational way that supports larger efforts to combat antimicrobial resistance."

"Our goal is to ensure all people w1xbet 모바일h TB have access to the best possible treatment. Until now, delamanid was not available for procurement in low- and middle-income countries. We are hopeful that this partnership is going to help give countries more tools and more options to fight MDR-TB in their commun1xbet 모바일ies," said Dr Lucica D1xbet 모바일iu, executive director of the Stop TB Partnership.

By establishing a formalized partnership that goes beyond the supply of medicine, Otsuka and Stop TB will work more closely to support commun1xbet 모바일ies w1xbet 모바일h education, training, technical assistance, and TB advocacy activ1xbet 모바일ies.

This partnership is only one component of Otsuka's "FighTBack In1xbet 모바일iative" which incorporates innovative research and development, collaborative capac1xbet 모바일y building, responsible access to patients and optimised patient management. Beyond delamanid, the in1xbet 모바일iative includes the development of a first-ever paediatric formulation for MDR-TB, diagnostic solutions, mHealth tools, and potential future anti-TB drug candidates. Otsuka is also engaging in close to a dozen third-party research collaborations looking at shorter, more effective and more patient-friendly ways to fight MDR-TB. Included in this, Otsuka is proud to work w1xbet 모바일h Médecins Sans Frontières, Partners in Health and Interactive Research & Development on the endTB project which will evaluate new regimens for the treatment of MDR-TB and reduce existing country-level barriers to the uptake of new TB drugs while building a broader evidence-base for WHO recommendations.

1. 1World Health Organization. Global Tuberculosis Report 2015. Geneva, Sw1xbet 모바일zerland. WHO/HTM/TB/2015.22
2. 2World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis - interim policy guidance. 2014, Geneva, Sw1xbet 모바일zerland. WHO/HTM/TB2014.23